32 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22620 | any line, RECIST 1.1 | Ahmad Hussein Awada | Multiple | Boehringer Ingelheim | 1367.1 | Trial closed | An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit | ahmad.awada@hubruxelles.be | 1 | 1 | |
| 22632 | any line, RECIST 1.1 | Philippe Aftimos | Multiple | Amcure GmbH | AMC303-01 | Trial closed | A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin | philippe.aftimos@hubruxelles.be | 1/1b | 1 | |
| 22744 | Second line | Joseph Kerger | Uterus | BGOG | BGOG-cx1/ENGOT-cx1 | Trial closed for recruitment | Randomized double-blind phase II study comparing 3-weekly carboplatin (AUC 5 or 6) + paclitaxel 175 mg/m2 with or without concomitant and maintenance Nintedanib in advanced or recurrent cervical carcinoma | joseph.kerger@hubruxelles.be | 2 | 2 | |
| 22766 | Any line, RECIST 1.1 | Ahmad Hussein Awada | Multiple | Gamamabs Pharma | C101 | Trial closed | Open, non-controlled, multicenter, first-in-human study for the evaluation of the safety, pharmacokinetics and preliminary antitumor activity of GM102 in patients with advanced pretreated gynecological cancer | ahmad.awada@hubruxelles.be | 1 | 1 | |
| 22758 | ECOG 0 or 1 | Ahmad Hussein Awada | Multiple | BMS - Bristol Myers Squibb int. | CA209358 | Trial closed | Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors | ahmad.awada@hubruxelles.be | 1/2 | 1 | |
| 22614 | Status WHO < 2. Adjuvant | Gabriel Liberale | Ovary | Unicancer | CHIPOR | Trial closed for recruitment | CHIPOR : randomized phase III study evaluating hypertermic intraperitoneal chemotherapy in the treatment of ovarian cancer relapse | gabriel.liberale@hubruxelles.be | 3 | 3 | |
| 28626 | Philippe Aftimos | Multiple | Lilly | EMBER | Trial closed for recruitment | A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Therapies for Patients with ER+, HER2-Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers | philippe.aftimos@hubruxelles.be | 1/1b | 1 | ||
| 29193 | Laura Polastro | Uterus | Seagen | ENGOT-cx12 - SGNTV-003 | Trial closed for recruitment | A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin versus Investigator's Choice Chemotherapy in Second or Third Line Recurrent or Metastatic Cervical Cancer | laura.polastro@hubruxelles.be | 3 | 3 | ||
| 22692 | any line / Lung metastasis | Konstantinos Stathopoulos | Lung | EORTC | EORTC 1658 | Trial closed | Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) | konstantinos.stathopoulos@hubruxelles.be | |||
| 22763 | Platinium-refractory | Joseph Kerger | Multiple | EORTC | EORTC 55092 | Trial closed | Phase IB-II, open label, multicentre feasibility study of pazopanib in combination with Paclitaxel and Carboplatin in patients with platinumrefractory/ resistant ovarian, fallopian tube or peritoneal carcinoma | joseph.kerger@hubruxelles.be | 1/2 | 1 | |
| 29003 | Laura Polastro | Ovary | Novartis | EPIK-O | Trial closed | A Phase III, multi-center, randomized (1:1), open-label, activecontrolled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer (EPIK-O / CBYL719K12301) | laura.polastro@hubruxelles.be | 3 | 3 | ||
| 22798 | Relasped/refractory patient | Christiane Jungels | Multiple | Imcheck | EVICTION | Trial open for recruitment | A fist-in-human, two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 as monotherapy and in combination with an Immune Checkpoint Inhibitor, in patients with advanced-stage, relapsed/refractory cancer | christiane.jungels@hubruxelles.be | 1 | 1 | |
| 22679 | Platinium resistant | Joseph Kerger | Ovary | Lilly | I4D-MC-JTJN | Trial closed | A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer | joseph.kerger@hubruxelles.be | 2 | 2 | |
| 22625 | RECIST 1.1, after standard trerapy | Ahmad Hussein Awada | Multiple | Lilly | I7W-MC-JQBA | Trial closed | A Phase 1 Study of LY3127804 as Monotherapy and in Combination with Ramucirumab in Patients with Advanced Solid Tumors | ahmad.awada@hubruxelles.be | 1 | 1 |